Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy

BACKGROUND: Although immune checkpoint inhibitors (ICIs) have been shown to yield promising therapeutic outcomes in a small subset of patients with triple negative breast cancer (TNBC), the majority of patients either do not respond or subsequently develop resistance. Recent studies have revealed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zaofeng, Sun, Jacquelyne Ka-Li, Lee, Marianne M, Chan, Michael K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476161/
https://www.ncbi.nlm.nih.gov/pubmed/36104100
http://dx.doi.org/10.1136/jitc-2022-005068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476161/
https://www.ncbi.nlm.nih.gov/pubmed/36104100
http://dx.doi.org/10.1136/jitc-2022-005068

Ejemplares similares